DUPIXENT is an add-on maintenance treatment for adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). It is the first biologic FDA approved in CRSwNP. DUPIXENT targets two of the sources of inflammation underlying the disease by inhibiting IL-4 and IL-13 signaling and is not an immunosuppressant or steroid.^1,a

FDA, US Food and Drug Administration.

^aThe mechanism of dupilumab action has not been definitively established.¹

See How Dupixent Works